Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users

Objectives  To identify factors influencing mortality in an HIV programme providing care to large numbers of injecting drug users (IDUs) and patients co‐infected with hepatitis C (HCV).

[1]  Helen M. Chun,et al.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. , 2012, The Journal of infectious diseases.

[2]  Louisa Degenhardt,et al.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews , 2011, The Lancet.

[3]  Jiahong Xu,et al.  Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002–09 , 2010, International journal of epidemiology.

[4]  J. Tassie,et al.  Trends in Retention on Antiretroviral Therapy in National Programs in Low-Income and Middle-Income Countries , 2010, Journal of acquired immune deficiency syndromes.

[5]  A. Calmy,et al.  Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. , 2010, JAMA.

[6]  J. Montaner,et al.  Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. , 2010, The Lancet. Infectious diseases.

[7]  Ross J. Harris,et al.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  H. Te,et al.  Epidemiology of hepatitis B and C viruses: a global overview. , 2010, Clinics in liver disease.

[9]  E. Ding,et al.  Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Ray Y. Chen,et al.  Five-Year Outcomes of the China National Free Antiretroviral Treatment Program , 2009, Annals of Internal Medicine.

[11]  B. Yip,et al.  Highly active antiretroviral therapy and survival in HIV-infected injection drug users. , 2008, JAMA.

[12]  J. Montaner,et al.  A review of barriers and facilitators of HIV treatment among injection drug users , 2008, AIDS.

[13]  B. Berkhout,et al.  Risk of Hepatitis-Related Mortality Increased Among Hepatitis C Virus/HIV-Coinfected Drug Users Compared With Drug Users Infected Only With Hepatitis C Virus: A 20-Year Prospective Study , 2008, Journal of acquired immune deficiency syndromes.

[14]  C. Rouzioux,et al.  Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia , 2007, AIDS.

[15]  J. Montaner,et al.  HIV treatment, injection drug use, and illicit drug policies , 2007, The Lancet.

[16]  A. León,et al.  Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area , 2007, HIV medicine.

[17]  S. Makombe,et al.  Risk factors for high early mortality in patients on antiretroviral treatment in a rural district of Malawi , 2006, AIDS.

[18]  I. Buchan,et al.  Adherence to HAART : A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators , 2006 .

[19]  S. Lai,et al.  HIV prevalence among injection drug users in rural Guangxi China. , 2006, Addiction.

[20]  S. Shade,et al.  Individual, Interpersonal, and Structural Correlates of Effective HAART Use Among Urban Active Injection Drug Users , 2006, Journal of acquired immune deficiency syndromes.

[21]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[22]  S. Lai,et al.  Coinfection with HIV and hepatitis C virus among injection drug users in southern China. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Montaner,et al.  Determinants of HAART discontinuation among injection drug users , 2005, AIDS care.

[24]  Paul D Cleary,et al.  Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. , 2005, Archives of internal medicine.

[25]  Richard D Moore,et al.  Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001 , 2005, Journal of acquired immune deficiency syndromes.

[26]  D. Collet.  Modelling Survival Data in Medical Research , 2004 .

[27]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[28]  Adrian Renton,et al.  Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. , 2003, Social science & medicine.

[29]  Christopher M. Taylor,et al.  Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients , 2003, Gut.

[30]  W. Bilker,et al.  Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. , 2002, AIDS.

[31]  D. Neau,et al.  Causes of death among HIV‐infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999 , 2002, HIV medicine.

[32]  J. Kaldor,et al.  Is severe liver disease a common outcome for people with chronic hepatitisC? , 2002, Journal of gastroenterology and hepatology.

[33]  D. Vlahov,et al.  Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users , 2001, AIDS.

[34]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[35]  A. Telenti,et al.  Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.

[36]  M. Wainberg,et al.  Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.

[37]  D. Collett.  Modelling Survival Data in Medical Research , 1994 .

[38]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[39]  T. Mainland.  UNGASS COUNTRY PROGRESS REPORT , 2008 .

[40]  Richard D Moore,et al.  Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. , 2006, Drugs.

[41]  N. Michael,et al.  Joint United Nations Programme on HIV/AIDS. , 2004, Military medicine.